Dexketoprofen – an additional opportunity to control chronic pain syndrome in malignant neoplasms
https://doi.org/10.21518/2079-701X-2019-10-172-178
Abstract
Chronic pain syndrome (CPS) is an independent disease. Patients with disseminated malignant tumors may experience chronic pain even with successful anticancer therapy. For the control of CPS use the WHO analgesic ladder. Despite adequate pain relief, patients may experience breakthrough pain. Clinical guidelines suggest the use of opioids for the treatment of breakthrough pain. Dexketoprofen is a nonsteroidal anti-inflammatory drug (NSAIDs) of rapid action. The drug is highly effective for pain in the bones of various origins. Dexketoprofen can be used for incident predictable breakthrough pain.
About the Author
I. A. Koroleva
rivate foundation of Educational establishment of Higher Education «Medical University «REAVIZ».
Russian Federation
Russian Federation
Dr. of Sci. (Med.), Professor of Chair for Clinical Medicine of Postgraduate Education, Private Institution «Educational Organization of Higher Education« Medical University «Reaviz».
References
1. World Cancer Report. World Health Organization, International Agency for Research on Cancer; eds.: B.W. Stewart, P. Kleihues. Lyon: IARC Press, 2003.
2. Merskey H., Bugduk N. Classification of Cronic Pain Syndromes and Definitions of Pain Terms 2nd ed. Seattle, WA: IASP Press, 1994.
3. Данилов А.Б., Данилов Ал.Б. Управление болью. Биопсихосоциальный подход. М.: АММ ПРЕСС, 2012, 568 с. [Danilov A.B., Danilov Al.B. Pain management. Biopsychosocial approach. M.: AMM PRESS, 2012, 568 p.] (In Russ).
4. Когония Л.М., Волошин А.Г., Новиков Г.А., Сидоров А.В. Практические рекомендации по лечению хронического болевого синдрома у онкологических больных. Злокачественные опухоли: Практические рекомендации RUSSCO #3s2. 2018. [Kogonia L.M., Voloshin A.G., Novikov G.A., Sidorov A.V. Practical guidelines for the management of chronic pain in cancer patients. Zlokhachestvennye Opukholi: Prakticheskie RekomendatsiiRUSSCO # 3s2. 2018.] (In Russ).
5. Клинические рекомендации «Хронический болевой синдром (ХБС) у взрослых пациентов, нуждающихся в паллиативной медицинской помощи». 2016, 60 с. http:// cr.rosminzdrav.ru/clin_recomend. [Clinical guidelines for chronic pain syndrome (CPS) in adult patients in need of palliative care. 2016, 60 p. http://cr.rosminzdrav.ru/clin_recomend.] (In Russ).
6. Паравина Е.В. Обезболивающие препараты в онкологии. Справочник поликлинического врача. 2014;10:53-56. [Paravina E.V. Painkillers in oncology. Spravochnik Poliklinicheskogo Vracha. 2014;10:53-56.] (In Russ).
7. Zeilhofer H.U., Brune K. Analgesic strategies beyond the inhibition of cyclooxygenases. Trends Pharmacol Sci. 2006;27(9):467–74.
8. Steinmeyer J. Pharmacological basis for the therapy of pain and inflammation with nonsteroidal anti-inflammatory drugs. Arthritis Res. 2000;2(5):379–85.
9. Семиглазова, Т.Ю., Филатова Л.В., Криворотько П.В. Качество жизни – важный критерий эффективности таргетной терапии метастатического поражения скелета при раке молочной железы. Опухоли женской репродуктивной системы. 2013;1–2:17–22. [Semiglazova T.Yu., Filatova L.V., Krivorotko P.V. Quality of life is an important criterion for the efficacy of targeted therapy for bone metastasis in breast cancer patients. Opukholi Zhenskoi Reproduktivnoi Sistemy. 2013;1–2:17–22.] (In Russ).
10. Моисеенко В.М., Блинов Н.Н. Метастатическое поражение костей при солидных опухолях и возможности использования клодроната (Бонефос) в клинической онкологии (обзор литературы). СПб., 1995. 47с. [Moiseenko V.M., Blinov N.N. Metastatic bone damage in solid tumours and the possibility of using clodronate (Bonefos) in clinical oncology (literature review). SPb., 1995. 47p.] (In Russ).
11. Xiang, J., Hurchla M.A., Fontana F., Su X. CXCR4 Protein Epitope Mimetic Antagonist, POL5551, Dis-rupts Metastasis and Enhances Chemotherapy Effect in Triple Negative Breast Cancer. Mol. Cancer Ther. 2015;12:103–107.
12. Nijenhuis M.V., Rutgers E.J. Conservative surgery for multifocal/multicentric breast cancer. Breast. 2015;21:161–167.
13. Большакова С.А., Хмелевский Е.В., Добровольская Н.Ю. Изменение болевого синдрома при проведении лучевой терапии и введении бисфосфонатов у пациенток с метастатическим поражением костей при раке молочной железы. Вестник Российского научного центра рентгенорадиологии Минздрава России. 2012;4(12):15. [Bolshakova S.A., Khmelevsky E.V., Dobrovolskaya N.Yu. Changes in pain syndrome during radiation therapy and the administration of bisphosphonates in breast cancer patients with metastatic bone lesions. Vestnik Rossiyskogo Nauchnogo Tsentra Rentgenoradiologii Minzdrava Rossii. 2012;4(12):15.] (In Russ).
14. Приказ Министерства здравоохранения Российской Федерации от 14 апреля 2015 г. №187н «Об утверждении Порядка оказания паллиативной медицинской помощи взрослому населению». https://www.rosminzdrav.ru/ documents. [Order of the Ministry of Health of the Russian Federation No. 187n On approval of the procedure for the provision of palliative medical care to the adult population» of April 14, 2015.https://www.rosminzdrav.ru/documents] (In Russ).
15. Stjernsward J. WHO cancer pain relief programme. Cancer Surv. 1988;7:195-208.
16. Enting R.H., van der Rijt C.C., et al. Treatment of pain in cancer with systemically administered opioids. Ned Tijdschr Geneeskd. 2001;19;145(20):950–954.
17. Davies A.N., Dickman A., Reid C. et al. the management of cancer-related breakthrough pain: Recommendations of a trask group of the Science Committee of the Association for Palliative Medicine of Great Britain and Irelend. Eur. J. of Pain. 2009;13:331-338.
18. Mercadante S., Portenoy R.K. Breakthrough cancer pain: twenty-five years of study. Pain. 2016;(157)12:2657-2663. Pablished online: December 2016, www.painjournalonline.com.
19. Gómez-Batiste X., Madrid F., Moreno F. et al. Breakthrough cancer pain: Prevalence and characteristics in patients in Catalonia, Spain. J. of Pain and Symp. Manag. 2002;24:45–52.
20. Zeppetella G., O’Doherty C.A., Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J. of Pain and Symp. Manag. 2000;20:87–92.
21. Davies A., Zeppetella G., Andersen S. et al. Multicentre European study of breakthrough cancer pain: Pain characteristics and patient perceptions of current and potential management strategies. Eur. J. of Pain. 2011;15:756–763.
22. Hwang S.S., Chang V.T., Kasimis B. Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain. 2003;101:55–64.
23. Textbook of palliative medicine and supportive care/second edition, 2015. Ed. by Bruera E., Higginson I., Gunten F., Morita T., et al. CRC Press Taylor & francis Group; 2015:506–511.
24. Greco M.T., Corli O., Montanari M. et al. Epidemiology and pattern of care of breakthrough cancer pain in a longitudinal sample of cancer patients: Results from the Cancer Pain Outcome Research Study Group. The Cl. J. of Pain. 2011;27:9–18.
25. Абузарова Г.Р., Лапина С.Е., Сарманаева Р.Р. «Прорывная боль» – новый термин, не новая проблема. Российский журнал боли. 2017;3-4(54):8-16. [Abuzarova G.R., Lapina S.E., Sarmanayeva R.R. Breakthrough pain is a new term, not a new problem. Rossiysky Zhurnal Boli. 2017;3-4(54):8-16.] (In Russ).
26. NCCN Guidelines Version 2.2019 Adult Cancer Pain. https://www.nccn.org.
27. Вознесенский А.Г. Клиническая фармакология нестероидных противовоспалительных средств. Волгоград, 1999, 186 c. Voznesensky A.G. Clinical pharmacology of nonsteroidal anti-inflammatory drugs. Volgograd, 1999, 186 p.] (In Russ).
28. Mauleon D., Artigas R., Garsia M.L., Carganico G. Preclinical and clinical development of dexketoprofen. Drugs. 1996;52(Suppl.5):24–46.
29. Moore R.A., Barden J. Systematic review of dexketoprofen in acute and chronic pain. BMC Clin Pharmacol. 2008. Oct 31;8:11.
30. Rodríguez M.J., Contreras D., Gálvez R. et al. Double-blind evaluation of short-term analgesic efficacy of orally administered dexketoprofen trometamol and ketorolac in bone cancer pain. Pain. 2003. Jul;104(1-2):103-110.
31. Moore R.A., Gay-Escoda C., Figueiredo R., et al. Dexketoprofen/tramadol: randomised doubleblind trial and confirmation of empirical theory of combination analgesics in acute pain. J Headache Pain. 2015;16:541.
32. Laporte J.R., Ibanez L. et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf. 2004;27(6):411–20.
Review
For citations:
Koroleva IA. Dexketoprofen – an additional opportunity to control chronic pain syndrome in malignant neoplasms. Meditsinskiy sovet = Medical Council. 2019;(10):172-178. (In Russ.) https://doi.org/10.21518/2079-701X-2019-10-172-178
Views:
731
Email this article 